CBPD-268

• UNSPSC Description:

  CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker)[1].

• Target Antigen:

  Histone Acetyltransferase; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cbpd-268.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(N1CC2=C(CC1)N([C@@H]3CC[C@H](CC3)CN4CC(C=C(C(N(C5CCC(NC5=O)=O)C6=O)=O)C6=C7)=C7C4)N=C2N8CCCC9=C8C=C(C(F)F)C(C%10=CN(N=C%10)C)=C9)=O

• Molecular Weight:

  819.90

• References & Citations:

  [1]Chen Z, et al. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. J Med Chem. 2024 Apr 11;67(7):5275-5304.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported